The patent estate protecting Wellbutrin XL(R) consists of two formulation patents (U. IMPAX markets its generic products through its Global Pharmaceuticals division and markets its branded products through the IMPAX Pharmaceuticals division. Wellbutrin XL[R] Tablets, 300 mg, marketed by GlaxoSmithKline, had 300 mg wellbutrin xl u. Forward-looking statements speak only as to the date on which they are made, and IMPAX undertakes no obligation to update publicly or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise. HAYWARD, Calif. "Safe Harbor" statement under the Private Securities Litigation 300 mg wellbutrin xl reform Act of 1995: To the extent any statements made in this news release contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management. Is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Additionally, where strategically appropriate, IMPAX has developed marketing partnerships to fully leverage its technology platform. We have based these forward-looking statements on our current expectations and 300 mg wellbutrin xl projections about future events. Has commenced a legal action in its own name, and in the name of SmithKline Beecham Corporation, against two companies that have filed abbreviated new drug applications (ANDAs) with the 300 mg wellbutrin xl united States Food and Drug Administration for generic versions of Wellbutrin XL(R) (bupropion hydrochloride extended-release tablets). In addition, it has been shown to meet all requirements for approval, including bioequivalence 300 mg wellbutrin xl to the branded drug, Wellbutrin XL[R] 300 milligram. About Wellbutrin XL(R) Wellbutrin XL(R) is the first and only once-daily norepinephrine dopamine reuptake inhibitor (NDRI) for the treatment of depression in adults. Food and Drug Administration ("FDA") and Canadian Therapeutic Products Directorate ("TPD") approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials and finished products, third parties, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company’s filings with the 300 mg wellbutrin xl securities and Exchange Commission ("SEC") and the Ontario Securities Commission ("OSC"). For more information, please visit the Company’s Web site at: www. Impaxlabs. Food and Drug Administration ("FDA") and Canadian Therapeutic Products Directorate ("TPD") approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials and finished products, third parties, the regulatory environment, fluctuations in 300 mg wellbutrin xl operating results and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission ("SEC") and the Ontario Securities Commission ("OSC"). IMPAX Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. — Teva Pharmaceuticals USA issues the following statement in response to the "Review of Therapeutic Equivalence Generic Bupropion XL 300 mg and Wellbutrin XL 300 mg" released by FDA on April 300 mg wellbutrin xl 16, 2008: Teva Pharmaceutical Industries Ltd. , headquartered in 300 mg wellbutrin xl israel, is among the top 20 pharmaceutical companies in the world and is the world’s leading generic pharmaceutical company. Additionally, where strategically appropriate, IMPAX has developed marketing partnerships to fully leverage its technology platform.